Sentinel-lymph-node biopsy in breast cancer

Lancet Oncology

Volumn 8, Issue 10, 2007, Pages 854-855

  Rutgers, Emiel ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN ANTIBODY;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CENTER; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FALSE NEGATIVE RESULT; HEALTH PRACTITIONER; HUMAN; INTERMETHOD COMPARISON; LETTER; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MANAGED CARE; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; SENTINEL LYMPH NODE BIOPSY;

EID: 34748909463     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70288-7     Document Type: Letter

References (15)

1. Lyman G., Giuliano A., Somerfield M., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
2. de Kanter A., Menke-Pluymers M., Wouters M., et al. 5-year follow-up of sentinel node negative breast cancer patients. Eur J Surg Oncol 32 (2006) 282-286
3. Schulze T., Mucke J., Markwardt J., et al. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 93 (2006) 109-119
4. Veronesi U., Galimberti V., Mariani L., et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 41 (2005) 231-237
5. Veronesi U., Paganelli G., Viale G., et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7 (2006) 983-990
6. Mansel R., Fallowfield L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98 (2006) 599-609
7. Purushotham A., Upponi S., Klevesath M., et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 23 (2005) 4312-4321
8. Krag D., Anderson S., Julian T., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8 (2007) 881-888
9. Nieweg O., Estourgie S., van Rijk M., and Kroon B. Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients. J Surg Oncol 87 (2004) 153-156
10. Uren R., Howman-Giles R., Chung D., and Thompson J. Role of lymphoscintigraphy for selective sentinel lymphadenectomy. Cancer Treat Res 127 (2005) 15-38
11. Cox C., Salud C., Cantor A., et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 193 (2001) 593-600
12. Hutchinson J., Chagpar A., Scoggins C., et al. University of Louisville Breast Sentinel Lymph Node Study. Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. Am J Surg 190 (2005) 903-906
13. Viale G., Sonzogni A., Pruneri G., et al. Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. J Surg Oncol 85 (2004) 123-128
14. Schule J., Frisell J., Ingvar C., and Bergkvist L. Sentinel node biopsy for breast cancer larger than 3 cm in diameter. Br J Surg 94 (2007) 948-951
15. Leitch A., Beitsch P., McCall L., et al. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg 190 (2005) 539-542